Autolus Therapeutics (AUTL) Income from Continuing Operations (2017 - 2025)
Autolus Therapeutics (AUTL) posted quarterly Income from Continuing Operations of 90360000.0 for Q4 2025, down 227.32% year-on-year from 70970699.9 in Q4 2024, and down 14.21% on a QoQ basis from 79118000.0 in Q3 2025.
Autolus Therapeutics (AUTL) Income from Continuing Operations (2017 - 2025) Analysis & Trends
Autolus Therapeutics (AUTL) has reported Income from Continuing Operations for 9 consecutive years, with 90360000.0 the latest figure, recorded in Q4 2025.
- Quarterly Income from Continuing Operations fell 227.32% year-over-year to 90360000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 287556000.0 (down 30.32% YoY) and the FY2025 annual result came in at 287556000.0, down 30.32% from the prior year.
- Income from Continuing Operations fell to 90360000.0 in Q4 2025 per AUTL's latest filing, from 79118000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for AUTL reached as high as 26979000.0 in Q4 2022 and fell as low as 90360000.0 in Q4 2025.
- A 5-year average of 50380300.0 and a median of 44159500.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations surged 64.23% — and 2025, when it slumped 227.32%.
- Year by year, Income from Continuing Operations stood at 41708000.0 in 2021, then soared by 35.31% to 26979000.0 in 2022, then plunged by 186.04% to 77171000.0 in 2023, then jumped by 64.23% to 27606000.0 in 2024, then sank by 227.32% to 90360000.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 90360000.0, 79118000.0, and 47917000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Autolus Therapeutics | 404.53 Mn | 103.82 Mn | -1.04 Mn | -90.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -90.36 Mn |
| Sep 30, 2025 | -79.12 Mn |
| Jun 30, 2025 | -47.92 Mn |
| Mar 31, 2025 | -70.16 Mn |
| Dec 31, 2024 | -27.61 Mn |
| Sep 30, 2024 | -82.09 Mn |
| Jun 30, 2024 | -58.27 Mn |
| Mar 31, 2024 | -52.69 Mn |
| Dec 31, 2023 | -77.17 Mn |
| Sep 30, 2023 | -45.85 Mn |
| Jun 30, 2023 | -45.55 Mn |
| Mar 31, 2023 | -39.81 Mn |
| Dec 31, 2022 | -26.98 Mn |
| Sep 30, 2022 | -42.77 Mn |
| Jun 30, 2022 | -42.06 Mn |
| Mar 31, 2022 | -37.06 Mn |
| Dec 31, 2021 | -41.71 Mn |
| Sep 30, 2021 | -33.99 Mn |
| Jun 30, 2021 | -33.17 Mn |
| Mar 31, 2021 | -33.27 Mn |